TY  - GEN 
AU  - Casarrubios, M.
AU  - Provencio, M.
AU  - Nadal, E.
AU  - Insa, A.
AU  - García Campelo, María del Rosario
AU  - Lazaro Quintela, Martín
AU  - Dómine, M.
AU  - Majem, M.
AU  - Rodriguez-Abreu, D.
AU  - Martinez-Marti, A.
AU  - De Castro Carpeño, J.
AU  - Cobo, M.
AU  - López Vivanco, G.
AU  - Del Barco, E.
AU  - Bernabé, R.
AU  - Viñolas, N.
AU  - Barneto Aranda, I.
AU  - Massuti, B.
AU  - Sierra-Rodero, B.
AU  - Martinez-Toledo, C.
AU  - Fernández-Miranda, I.
AU  - Serna-Blanco, R.
AU  - Romero, A.
AU  - Calvo, V.
AU  - Cruz-Bermúdez, A.
PY  - 2022
SN  - 2051-1426
UR  - http://hdl.handle.net/20.500.11940/20878
AB  - BACKGROUND: Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus...
LA  - eng
TI  - Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
DO  - 10.1136/jitc-2022-005320
KW  - AS Coruña
KW  - CHUAC
KW  - INIBIC
KW  - AS Vigo
KW  - CHUVI
KW  - IISGS
VL  - 10
ER  -